Humira (adalimumab) is an antibody pharmaceutical. Adalimumab was first approved as Humira on 2002-12-31. It is used to treat ankylosing spondylitis, crohn disease, hidradenitis suppurativa, juvenile arthritis, and psoriatic arthritis amongst others in the USA. It has been approved in Europe to treat ankylosing spondylitis, arthritis, crohn disease, hidradenitis suppurativa, and juvenile arthritis amongst others. The pharmaceutical is active against tumor necrosis factor.
|Indication||ankylosing spondylitis, arthritis, crohn disease, hidradenitis suppurativa, juvenile arthritis, papulosquamous skin diseases, psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, uveitis|
|Drug Class||Monoclonal antibodies|